Rivaroxaban Versus Aspirin in Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With Recent Embolic Stroke of Undetermined Source (ESUS) (NAVIGATE ESUS)

What is the purpose of this trial?

The purpose of the study is to evaluate whether rivaroxaban is superior to aspirin in reducing the risk of recurrent stroke and systemic embolism in patients with recent ESUS


Participation Guidelines

Ages: 18 years and older

Gender: Both


Bayer Healthcare Pharmaceuticals, Inc.

Dates: 08/29/2015 - 01/31/2018

Last Updated: 02/23/2016

Study HIC#: 1505015783

Get Involved

For more information about this study, contact:
Sonya Zhou
203-889-7192
sonya.zhou@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image